Stock Rich List
#7002 on the rich list of 14,644 insiders

Raymond Debbane

Director at Lexicon Pharmaceuticals; Insider at WW International. Based in The Woodlands, Texas.

$13.5M
in disclosed stock, −$461K (−3.30%) today
Market closed. Prices as of Nov 19, 4:04 PM ET
Rank
7002nd of 14,644
Companies held
2
Largest holding
LXRX, 92.1% of total
Latest SEC filing
Jun 3, 2026
Listed but not counted
$74.0M

What the $13.5M is made of

Holdings counted

All filings on SEC.gov
CompanyHow heldSharesPriceValueShare of totalReported
Lexicon Pharmaceuticals LXRX
Common Stock
Through Invus US Partners LLC5,451,204$1.67$9.1M67.4%Form 4, Jun 3, 2026
Lexicon Pharmaceuticals LXRX
Common Stock
Directly1,995,498$1.67$3.3M24.7%Form 4, Jun 3, 2026
WW International WW
Common Stock
Directly134,387$7.97$1.1M7.9%Form 4, May 9, 2023

Share counts are the amounts Raymond Debbane reported owning after each line of their latest filing for that company, adjusted for any later stock splits. Values use the latest price. Methodology.

Reported but not counted

These shares appear on Raymond Debbane's filings but are held for charities, by investment funds the insider manages, or could not be valued reliably. Insiders usually disclaim ownership of fund holdings beyond their personal stake.

CompanyHow heldSharesPriceValueShare of totalReported
Lexicon Pharmaceuticals LXRX
Common Stock
Through Invus, L.P. and related parties
Held by an investment fund or partnership
35,402,689$1.67$59.1M—Form 4, Jun 3, 2026
Lexicon Pharmaceuticals LXRX
Common Stock
Through Invus Public Equities, L.P. and related parties
Held by an investment fund or partnership
7,362,368$1.67$12.3M—Form 4, Jun 3, 2026
Lexicon Pharmaceuticals LXRX
Common Stock
Through Avicenna Life Sci Master Fund LP and related parties
Held by an investment fund or partnership
1,538,462$1.67$2.6M—Form 4, Jun 3, 2026

Open-market trades, last 12 months

DateTradeCompanySharesPriceValueFiling
Feb 25, 2026BoughtLXRX2,000$1.49$3KView
Feb 23, 2026BoughtLXRX100,000$1.47$147KView
Feb 20, 2026BoughtLXRX100,000$1.48$148KView
Feb 19, 2026BoughtLXRX50,000$1.44$72KView
Feb 18, 2026BoughtLXRX133,688$1.32$176KView
Feb 17, 2026BoughtLXRX76,857$1.31$101KView
Feb 13, 2026BoughtLXRX57,952$1.31$76KView

Nearby on the list

Full list
Nearby ranks
RankNameStock holdingsToday
6999John E. Maupin, Jr., D.D.S
Director, Encompass Health. Lakewood Ranch, FL
$13.5M−$271K (−1.96%)
7000John T. Schwieters
Director, Danaher. Waltham, MA
$13.5M−$69K (−0.51%)
7001James P. Snee
PRESIDENT AND CEO, Hormel Foods. Phoenix, AZ
$13.5M−$77K (−0.56%)
7002Raymond Debbane
Director, Lexicon Pharmaceuticals. The Woodlands, TX
$13.5M−$461K (−3.30%)
7003Paul James Lawrence
SVP & Chief Financial Officer, Commercial Metals. Irving, TX
$13.5M−$382K (−2.75%)
7004Kenneth A. Jacobson
Chief Financial Officer, Avnet. Phoenix, AZ
$13.5M−$357K (−2.58%)
7005Regina L. Gregory
See Remarks, Targa Resources. Houston, TX
$13.5M−$225K (−1.64%)

Questions

How much stock does Raymond Debbane own?

Raymond Debbane holds $13,507,057 in listed stock based on SEC filings and current prices, mostly Lexicon Pharmaceuticals (LXRX). That ranks 7002nd on the Stock Rich List.

Is this Raymond Debbane's net worth?

No. It counts only listed shares reported on SEC Forms 3, 4 and 5. Cash, private companies, real estate, options and holdings that don't need to be reported are not included, so total net worth is likely different.

When did Raymond Debbane last buy or sell stock?

The most recent open-market trade on file is a purchase of 2,000 LXRX shares on Feb 25, 2026 at $1.49.